Last reviewed · How we verify
NCT04641728
Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer
Status unknown
Phase 2
Last updated 9 August 2022
What this trial tests
Phase 2 trial testing Pembrolizumab in Cervical Cancer in 28 participants. Status unknown.
Timeline
1 January 2021
Primary endpoint
31 December 2022
31 December 2022
31 December 2023
Quick facts
| Lead sponsor | Saitama Medical University International Medical Center |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 28 |
| Start date | 1 January 2021 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- Pembrolizumab (pembrolizumab) — full drug profile →
- Olaparib (olaparib) — full drug profile →
Conditions studied
- Cervical Cancer — all drugs for Cervical Cancer →
Sponsor
Saitama Medical University International Medical Center
Who can join
20 and older, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is a multicenter, single-arm, phase 2 study of pembrolizumab in combination with olaparib in recurrent or metastatic cervical cancer patients who had disease progression during or after platinum-based chemotherapy.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.
Shi C, Qin K, Lin A, Jiang A, et al · · 2022 · cited 60× · PMID 36071479 · DOI 10.1186/s13046-022-02469-0 -
Immune checkpoint inhibitors in cervical cancer: Current status and research progress.
Xie Y, Kong W, Zhao X, Zhang H, et al · · 2022 · cited 28× · PMID 36387196 · DOI 10.3389/fonc.2022.984896 -
Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions.
Ye J, Zheng L, He Y, Qi X. · · 2023 · cited 27× · PMID 37719443 · DOI 10.1002/mco2.368 -
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
Hunia J, Gawalski K, Szredzka A, Suskiewicz MJ, et al · · 2022 · cited 25× · PMID 36533080 · DOI 10.3389/fmolb.2022.1073797 -
Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review.
Maiorano BA, Maiorano MFP, Ciardiello D, Maglione A, et al · · 2022 · cited 14× · PMID 36497437 · DOI 10.3390/cancers14235955 -
Recent advances in immunotherapy for cervical cancer.
Ogasawara A, Hasegawa K. · · 2025 · cited 13× · PMID 39888529 · DOI 10.1007/s10147-025-02699-0 -
Unleashing the Power of Synthetic Lethality: Augmenting Treatment Efficacy through Synergistic Integration with Chemotherapy Drugs.
Du Y, Luo L, Xu X, Yang X, et al · · 2023 · cited 8× · PMID 37896193 · DOI 10.3390/pharmaceutics15102433 -
Harnessing Synthetic Lethal Interactions for Personalized Medicine.
Shieh GS. · · 2022 · cited 7× · PMID 35055413 · DOI 10.3390/jpm12010098
Verify or expand the search:
- PubMed search for NCT04641728
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pembrolizumab
Trials testing the same drug.
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
Other recruiting trials for Cervical Cancer
Currently open trials in the same condition.
- NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
- NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
- NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04641728 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Saitama Medical University International Medical Center
- Last refreshed: 9 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04641728.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing